Drug Trial Radar · NCT06223932
Evaluation of the Efficacy and Safety of Molnupiravir Treatment in Mild/Moderate Covid-19 Patients.
Last checked: Nov 19, 2026Latest source record: Jan 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,600
Planned (sponsor's estimate)
Start
Jul 7, 2022
Primary completion
Feb 2024
Study completion Feb 2024
Sponsor
- Lead sponsor
- Serap YavuzAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- MDX Klinik Araştırma Egitim ve Danismanlik Ltd. Sti.
- First posted
- Jan 25, 2024
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluation of the Efficacy and Safety of Molnupiravir Treatment in Mild/Moderate Covid-19 Patients. Turkey Cohort, Prospective, Observational, Comparative Study In the antiviral treatment of COVID-19, molnupiravir, an RdRp (RNA-dependent RNA polymerase) inhibitor, was the first agent shown to reduce death and hospitalization in a reliable/adequate phase-3 clinical trial. For this reason, molnupiravir has been approved for emergency use in many countries, including Turkey, as it is still an unmet need in the treatment of COVID-19. However, it is not yet known which factors related to the patient or the disease are important for this drug to be effective. In addition, since this is the first time it will be widely used, rare or long-term adverse effects have not been identified. Since molnupiravirin is known to exert antiviral activity by inducing mutations in the virus, there are some hypotheses that this effect may lead to the emergence of new and more dangerous variants.
Conditions
- COVID-19
- SARS-CoV-2 Infection
Interventions
MolnupiravirDrug
COVID-19 diagnosed patients receiving molnupiravir will be evaluated to show if Molnupiravir is effective in reducing the combined outcome of hospitalization/death due to COVID-19 in the first 28 days when used in real life.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Molnupiravir effectineness in reducing the combined outcome of hospitalization/death due to COVID-19 in the first 28 days when used in real lifeTime frame: 28 Days, 3 month and 6 month follow-up after diagnose and treatment
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Ankara City Hospital
Ankara, Turkey (Türkiye)
Ankara University Faculty of Medicine
Ankara, Turkey (Türkiye)
CAM and SAKURA Training and Research Hospital
Istanbul, Turkey (Türkiye)
Istanbul Haseki Training and Research Hospital
Istanbul, Turkey (Türkiye)
Koc University Hospital
Istanbul, Turkey (Türkiye)
Umraniye Training and Research Hospital
Istanbul, Turkey (Türkiye)
Istanbul University, Istanbul Faculty of Medicine, Department of Infectious Disease
Istanbul, Fatih, Turkey (Türkiye)
Cerrahpasa Faculty of Medicine Infectious Disease Departament
Istanbul, Fatih, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.